This article is more than 5 years old. Information may no longer be current.

ThromboGenics announces positive long-term study results of Jetrea in VMA patients

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ThromboGenics announced positive topline results from the OASIS study of Jetrea in patients with symptomatic vitreomacular adhesion, according to a press release.

The randomized, sham-controlled, double-masked study collected data to determine the long-term safety and efficacy of Jetrea (ocriplasmin) injection in a 24-month follow-up period for the treatment of vitreomacular adhesion (VMA). It is the company’s first controlled study of the product since results of its phase 3 program were announced in 2011, the release said.

At day 28, 41.7% of patients achieved VMA resolution with Jetrea injection compared with 6.2% of patients who achieved resolution with sham injection (P < .001) . The safety profile at 24 months was consistent with Jetrea’s overall safety profile, and no new safety events were identified, the release said.

Study data show patient selection is important in achieving a higher rate of VMA resolution with Jetrea. Retina physicians have used advanced diagnostic technology to select patients with focal VMA and no epiretinal membrane, which leads to better outcomes, the release said.

Analysis is ongoing, and ThromboGenics plans to release further results later this year.